Phenytoin Extended-Release Capsules and Wakix Tablets
Determining the interaction of Phenytoin Extended-Release Capsules and Wakix Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.ADJUST DOSE: Coadministration with potent CYP450 3A4 inducers may decrease the systemic exposure and efficacy of pitolisant. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of pitolisant, which has been shown to be metabolized by this isoenzyme. Concomitant use with the potent CYP450 3A4 inducer rifampin decreased the mean peak plasma concentration (Cmax) and area under the plasma concentration-time curve ratio (AUC ratio) by 39% and 50%, respectively. MANAGEMENT: Patients should be assessed for loss of efficacy of pitolisant following initiation of a potent CYP450 3A4 inducer, and the pitolisant dosage adjusted as necessary. For patients already receiving a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, the dose of pitolisant should be increased to double the original daily dose (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days. The dosage of pitolisant should be reduced by half if concomitant use of a strong CYP450 3A4 inducer is discontinued. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Wakix (pitolisant)." Harmony Biosciences, LLC, Plymouth Meeting, PA.
Professional:ADJUST DOSE: Coadministration with potent CYP450 3A4 inducers may decrease the systemic exposure and efficacy of pitolisant. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of pitolisant, which has been shown to be metabolized by this isoenzyme. Concomitant use with the potent CYP450 3A4 inducer rifampin decreased the mean peak plasma concentration (Cmax) and area under the plasma concentration-time curve ratio (AUC ratio) by 39% and 50%, respectively.
MANAGEMENT: Patients should be assessed for loss of efficacy of pitolisant following initiation of a potent CYP450 3A4 inducer, and the pitolisant dosage adjusted as necessary. For patients already receiving a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, the dose of pitolisant should be increased to double the original daily dose (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days. The dosage of pitolisant should be reduced by half if concomitant use of a strong CYP450 3A4 inducer is discontinued.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Wakix (pitolisant)." Harmony Biosciences, LLC, Plymouth Meeting, PA.
Generic Name: phenytoin
Brand name: Dilantin, Phenytek, Dilantin Infatabs, Phenytoin Sodium, Prompt
Synonyms: Phenytoin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Phenytoin Extended-Release Capsules-Wal-Fex
- Phenytoin Extended-Release Capsules-Wal-finate
- Phenytoin Extended-Release Capsules-Wal-itin
- Phenytoin Extended-Release Capsules-Wal-Zyr D
- Phenytoin Extended-Release Capsules-Walgreens Ibuprofen Junior Strength
- Phenytoin Extended-Release Capsules-Warfarin
- Wakix Tablets-Phenytoin Infatabs
- Wakix Tablets-Phenytoin injection
- Wakix Tablets-Phenytoin Intravenous
- Wakix Tablets-Phenytoin Oral Suspension
- Wakix Tablets-Phenytoin Sodium
- Wakix Tablets-Phenytoin Sodium, Prompt injection